Literature DB >> 30123558

Editorial on "upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer".

Hongsheng Lin1, Kun Qiao1.   

Abstract

Entities:  

Year:  2018        PMID： 30123558      PMCID： PMC6072932          DOI： 10.21037/jtd.2018.06.154

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

Review 1.  Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer.

Authors:  Paul E Van Schil; Krishan Yogeswaran; Jeroen M Hendriks; Patrick Lauwers; Corinne Faivre-Finn
Journal:  Expert Rev Anticancer Ther       Date:  2017-04-21       Impact factor: 4.512

Review 2.  Surgical treatment of stage III non-small cell lung cancer.

Authors:  Paul E Van Schil; Michèle De Waele; Jeroen M Hendriks; Patrick R Lauwers
Journal:  Eur J Cancer       Date:  2009-09       Impact factor: 9.162

Review 3.  Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.

Authors:  Shun-Ichi Watanabe; Kazuo Nakagawa; Kenji Suzuki; Kazuya Takamochi; Hiroyuki Ito; Jiro Okami; Keiju Aokage; Hisashi Saji; Hiroshige Yoshioka; Yoshitaka Zenke; Tadashi Aoki; Yasuhiro Tsutani; Morihito Okada
Journal:  Jpn J Clin Oncol       Date:  2017-12-01       Impact factor: 3.019

4.  Microscopic N2 disease exhibits a better prognosis in resected non-small-cell lung cancer.

Authors:  Elena Garelli; Stéphane Renaud; Pierre-Emmanuel Falcoz; Noëlle Weingertner; Anne Olland; Nicola Santelmo; Gilbert Massard
Journal:  Eur J Cardiothorac Surg       Date:  2016-02-25       Impact factor: 4.191

5.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

Authors:  Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

6.  Upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer.

Authors:  Difan Zheng; Ting Ye; Hong Hu; Yawei Zhang; Yihua Sun; Jiaqing Xiang; Haiquan Chen
Journal:  J Thorac Cardiovasc Surg       Date:  2017-11-03       Impact factor: 5.209

7.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

Review 8.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Authors:  Wilfried E E Eberhardt; Alan Mitchell; John Crowley; Haruhiko Kondo; Young Tae Kim; Andrew Turrisi; Peter Goldstraw; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

9.  Optimal managements of stage IIIA (N2) non-small cell lung cancer patients: a population-based survival analysis.

Authors:  Zhaofei Pang; Yufan Yang; Nan Ding; Cuicui Huang; Tiehong Zhang; Yang Ni; Jiajun Du; Qi Liu
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.